Home / Drug discovery / Chemistry / Speciality chemistry
Specialty chemistry CRO services
We offer parallel chemistry services to accelerate hit-to-lead and lead optimization programs. Our experienced chemists design and synthesize compound libraries, combining CRO specialty chemistry expertise with advanced enabling techniques such as photochemistry-like flow chemistry, chemo- and biocatalysis, isotope labeling chemistry, chiral chemistry, and electrochemistry.
Semi-automated workflows and scalable purification ensure efficient exploration of chemical space, delivering high-quality compounds that drive faster, more confident discovery decisions.
- Expert teams, proven results – Decades of parallel chemistry experience across discovery programs, delivering diverse, high-quality compound libraries with precision and speed.
- Smart, scalable workflows – Semi-automated reaction setups and high-throughput purification reduce timelines and maintain reproducible quality at every scale.
- Advanced enabling chemistry – Access novel scaffolds and transformations using electrochemistry, photochemistry and flow chemistry for greater chemical diversity.
- Flexible library design – From small, focused sets to >500-compound libraries, tailored to your target class and project needs.
- Collaborative engagement models – Work with us on single-project or FTE-based programs for transparent communication and continuity throughout discovery.
Related services
Parallel chemistry expertise
80,000-compound SymeGold library
Curated for novelty, chemical tractability and diversity to expand discovery options and improve screening success.
Precision at scale
Streamlined parallel workflows deliver large, high-quality libraries efficiently, cutting redundancy and keeping programs focused and productive.
Decades of discovery expertise
Experienced chemists and data-driven design help you explore chemical space smarter and identify better candidates faster.
Connected chemistry expertise
Alongside parallel chemistry, we combine medicinal chemistry, flexible synthetic chemistry and computational insights to turn library data into clear next steps.
Early design and scalable synthesis are guided by real-time analysis, ensuring each compound series is purposeful and progression-ready.
The result is faster, more informed movement from discovery ideas to viable candidate molecules.
What do our partners say?
“I would like to extend my thanks for the excellent work Symeres has done in synthesizing the API for Part 1 of our project. Your communication throughout the process was outstanding, and the sense of urgency with which you operated allowed us to complete this phase promptly and efficiently.”
Leader
Large biotech
“They’ve always met or exceeded my expectations - that’s why I continue to come back, company after company, year after year.”
Allen Horhota, Vice-President Platform & Delivery
Seamless Therapeutics
“We’ve been with them…over 10 years. The cost, the flexibility - the value is just so strong. That’s why we’ve stuck with them.”
Senior Director, CMC
Biotech
“The progression was really phenomenal. I am truly impressed. There is a world of difference between you and other CROs.”
Start-up Founder
Biotech
“If the compound can be made, Symeres will undoubtedly find out a good way to make it.”
Dooyoung Jung, CEO
Pinotbio
“The team is making short work of these targets, so we will have to start thinking of some additional targets!”
Director
Biotech
“We are developing the most complex molecule that is built at this time in the world…We work with a lot of CROs, also chemistry CROs, and so far Symeres has done the best job with respect to transparency and also to troubleshoot the problems and find a solution. Over the years we have been really impressed with the work that Symeres has done.”
Founder
Biotech
“Through our dedicated FTE resource at Symeres we have achieved remarkable results, not only by developing a new “aspirational” synthetic route but also by significantly improving the current one to deliver a sustainable route for commercial production and giving us two options for late development.”
Associate Director
Large pharma, Europe
“A sign that things are going well - we keep coming to you. We’ve given Symeres five or six different projects already. That’s almost unheard of for us.“
Senior Director, Manufacturing
Top 10 global pharma
Your discovery and development partner
Symeres supports small-molecule programs from discovery through IND with openness, agility and scientific depth.
Our connected teams in Europe and North America have expertise across chemistry, biology, ADME and development and share data transparently, adapt quickly to new results, and stay accountable from first experiments to IND, to keep your progress clear, connected and continuous.
Resources we think you'll love
Blog
CDMO red flags you can’t ignore: Regulatory shortfalls and misalignment
Whitepaper
5 CDMO red flags you can’t ignore: A guide for biotechs and pharma
Blog
CDMO red flags you can’t ignore: Underestimating technology transfer complexity
Blog
O.N.E Symeres: A practical approach to real-world drug development
Blog
CDMO red flags you can’t ignore: Undefined or shifting project scope
Whitepaper
Accelerating chemical innovation: Unveiling Symeres’ parallel chemistry
Webinar | On-demand
From racemic to pure the art and science of enantiomer separation
Whitepaper
IND & IMPD enabling developability roadmap
Whitepaper
Innovations in unnatural amino acids: Advancing functional diversity and applications
Whitepaper
Leveraging copper-catalyzed ullmann-type cross-coupling reactions in PR&D
Whitepaper
Managing nitrosamines in the pharmaceutical industry: A comprehensive approach
Whitepaper
Optimizing solid-state properties and enhancing API bioavailability through physicochemical prediction
Whitepaper
Stable isotope-labeled compounds
Whitepaper
Unlocking the potential of high-throughput screening: Symegold library design and expansion insights
Interviews
Insights into drug discovery and development 2025
Interviews
Interview with the computer-aided drug design (CADD) department
Interviews
Meet the Organix Director, Mario Gonzalez
Interviews
Interview with the new Managing Director of Symeres Groningen
Interviews
An interview with Yadan Chen and Paul O’Shea
Interviews
An interview with Anu Mahadevan and Paul Blundell
Blog
Crystalline and liquid crystalline 25-hydroxy-cholest-5-en-3-sulfate sodium and methods for preparing same
Webinar | On-demand
In vivo pharmacokinetic experiments in preclinical drug development
Webinar | On-demand
Accelerating medicinal chemistry by rapid analoging
Webinar | On-demand
Solid-state chemistry part II: Optimal form selection by controlled crystallization
Webinar | On-demand
Route scouting for kilogram-scale manufacturing of APIs
Webinar | On-demand
Solid-state chemistry part I: Introduction
Speak with our parallel chemistry experts
See how we can support the discovery and development of your next breakthrough.